RNAi Roundtable: Patisiran, in Development for the Treatment of Hereditary ATTR Amyloidosis

RNAi Roundtable: Patisiran, in Development for the Treatment of Hereditary ATTR Amyloidosis

On August 3, 2017, we hosted an online RNAi Roundtable to review the progress with patisiran, an RNAi therapeutic in development for the treatment of hereditary ATTR amyloidosis.

View the presentation

Read the transcript

  • Jared Gollob, M.D., Vice President, Clinical Research
  • Moderator: Eric Green, Vice President, General Manager, TTR Program
  • Guest Speaker: Michael Polydefkis, M.D., Director, Cutaneous Nerve Lab, Professor of Neurology, Johns Hopkins University School of Medicine


SIGN UP FOR PATIENT CONNECT

Receive updates on our investigational therapies and clinical trials.